[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.209.213. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
September 1990

Cardiovascular and Intraocular Pressure Effects and Plasma Concentrations of Apraclonidine

Author Affiliations

From the Glaucoma Service and Biostatistics Center, The Wilmer Ophthalmological Institute, and the Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Md (Drs Coleman, Robin, Pollack, and Rudikoff and Ms Enger); the Departments of Ophthalmology and Medicine, Sinai Hospital, Baltimore (Drs Coleman, Robin, Pollack, and Rudikoff); and Alcon Laboratories, Fort Worth, Tex (Dr Mayer).

Arch Ophthalmol. 1990;108(9):1264-1267. doi:10.1001/archopht.1990.01070110080029
Abstract

• We performed a double-masked, crossover study comparing the cardiovascular and intraocular pressure effects of 0.5% and 0.25% topical apraclonidine hydrochloride and 0.5% timolol maleate in 20 healthy female volunteers. The contralateral effects of unilateral apraclonidine and the plasma concentrations of apraclonidine were also assessed. All measurements were done 2, 5, and 8 hours after drop instillation. A 15-minute treadmill test was performed after the 2-hour measurements. All three active medications lowered intraocular pressure comparably. There was no significant contralateral intraocular pressure effect seen with apraclonidine. The apraclonidine plasma concentrations were variable and unrelated to the amount of intraocular pressure lowering and cardiovascular parameters measured. Apraclonidine did not affect blood pressure or heart rate any differently than placebo. Timolol, however, blunted exercise-induced tachycardia. There were no significant differences in pupillary diameters or interpalpebral fissure widths among treatment groups.

×